Formoterol

79 interactions 5 explained in plain English

Also sold as: Perforomist

Medically reviewed by Dr. Brian Staiger, PharmD, BCPS · Updated Jul 4, 2026 · Editorial policy · Data sources

Sources: FDA prescribing information (Structured Product Labeling), the published literature cited in each entry, DDInter 2.0 (a major open-access drug-interaction database), and legacy DrugBank interaction data distributed by the NIH's RxNav service (decommissioned in 2024) — analyzed and reviewed by our pharmacist team. How we build this library →

Most serious with: Loperamide Moxifloxacin Ophthalmic Anagrelide Disopyramide Dolasetron Injection Atenolol

77 Major 2 Moderate

All (79) Major (77) Moderate (2)

Major

Formoterol Amitriptyline Elavil Explained Increased risk of QT interval prolongation and an increased risk of cardiovascular adverse effects Details Formoterol Sertraline Explained An increased risk of QT interval prolongation Details Formoterol Buprenorphine Belbuca Explained An increased risk of QT interval prolongation Details Formoterol Relugolix Orgovyx Explained Increased risk of QT interval prolongation Details Formoterol Amisulpride Injection Barhemsys Increased risk of serious ventricular arrhythmias such as torsades de pointes Details Formoterol Arsenic Trioxide Trisenox Increased risk of QT interval prolongation and an increased risk of cardiovascular adverse effects Details Formoterol Aripiprazole Injection Abilify An increased risk of QT interval prolongation Details Formoterol Arsenic Trioxide Injection Trisenox Increased risk of QT interval prolongation and an increased risk of cardiovascular adverse effects Details Formoterol Asenapine Transdermal Patch Secuado Increased risk of QT interval prolongation and an increased risk of cardiovascular adverse effects Details Formoterol Atenolol Tenormin Explained Reduced efficacy of formoterol or reduced efficacy of beta-adrenergic blocker Details Formoterol Azithromycin AzaSite Increased risk of QT interval prolongation and an increased risk of cardiovascular adverse effects Details Formoterol Acebutolol Sectral® Reduced efficacy of formoterol or reduced efficacy of beta-adrenergic blocker Details Formoterol Alfuzosin UroXatral Increased risk of QT interval prolongation and an increased risk of cardiovascular adverse effects Details Formoterol Anagrelide Agrylin Increased risk of QT interval prolongation Details Formoterol Bedaquiline Sirturo Increased risk of QT interval prolongation and an increased risk of cardiovascular adverse effects Details Formoterol Betaxolol Betoptic S Reduced efficacy of formoterol or reduced efficacy of beta-adrenergic blocker Details Formoterol Betaxolol Ophthalmic Betoptic® Reduced efficacy of formoterol or reduced efficacy of beta-adrenergic blocker Details Formoterol Bisoprolol Zebeta® Reduced efficacy of formoterol or reduced efficacy of beta-adrenergic blocker Details Formoterol Chloroquine Aralen® Increased risk of QT-interval prolongation Details Formoterol Dasatinib Phyrago An increased risk of QT interval prolongation Details Formoterol Degarelix Injection Firmagon Increased risk of QT interval prolongation Details Formoterol Deutetrabenazine Austedo An increased risk of QT interval prolongation Details Formoterol Disopyramide Norpace Increased risk of QT interval prolongation and an increased risk of cardiovascular adverse effects Details Formoterol Dofetilide Tikosyn Increased risk of QT interval prolongation and an increased risk of cardiovascular adverse effects Details Formoterol Dolasetron Anzemet Increased risk of QT interval prolongation and an increased risk of cardiovascular adverse effects Details Formoterol Dolasetron Injection Anzemet Increased risk of QT interval prolongation and an increased risk of cardiovascular adverse effects Details Formoterol Encorafenib Braftovi Increased risk of QT interval prolongation Details Formoterol Entrectinib Rozlytrek An increased risk of QT interval prolongation Details Formoterol Eribulin Injection Halaven Increased risk of QT interval prolongation and an increased risk of cardiovascular adverse effects Details Formoterol Esmolol Brevibloc Reduced efficacy of formoterol or reduced efficacy of beta-adrenergic blocker Details Formoterol Famotidine Calmicid Increased risk of QT interval prolongation and an increased risk of cardiovascular adverse effects Details Formoterol Famotidine Injection Calmicid Increased risk of QT interval prolongation and an increased risk of cardiovascular adverse effects Details Formoterol Felbamate Felbatol Increased risk of QT interval prolongation and an increased risk of cardiovascular adverse effects Details Formoterol Flecainide Tambocor® Increased risk of QT interval prolongation and an increased risk of cardiovascular adverse effects Details Formoterol Foscarnet Injection Foscavir Increased risk of QT interval prolongation Details Formoterol Fostemsavir Rukobia Increased risk of torsade de pointes Details Formoterol Furosemide Injection Disal An increased risk of ECG changes or hypokalemia Details Formoterol Galantamine Razadyne Increased risk of QT interval prolongation and an increased risk of cardiovascular adverse effects Details Formoterol Gatifloxacin Ophthalmic Zymar® Increased risk of QT interval prolongation and an increased risk of cardiovascular adverse effects Details Formoterol Gemifloxacin Factive Increased risk of QT interval prolongation and an increased risk of cardiovascular adverse effects Details

Check another drug

Still have questions about this combination?

Every question gets a real answer from a licensed pharmacist — free, and usually within a day.

Ask the pharmacist

Educational information only, not medical advice. Always confirm interactions with your pharmacist or prescriber before making any change to your medications.